Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genotyping and the High-Throughput Legacy

This article was originally published in Start Up

Executive Summary

A deluge of DNA sequence and gene expression data generated in the last five years encouraged the original high-throughput mentality within genomics companies. Mapping the human genome provided the impetus for developing technologies for high-throughput DNA sequencing and analysis. Now genotyping, or the detection and analysis of individual genetic variations, has become the newest market around which companies are preaching the need for high-throughput methodologies.While only a handful of companies were directly involved in assisting the Human Genome Project, genotyping--the detection and analysis of individual genetic variations--has been fueling technology development, with applications in basic research through drug development. But in genotyping, high throughput is the goal but is not yet the reality. On the other hand, even if it's early to be talking about the successful integration of genotyping technologies and data, current players are already pushing their technologies onto their customers' platforms. If a company isn't already a player, it may be too late.

You may also be interested in...



deCODE Re-Emerges: Can a Genomics Platform Model Work in Diagnostics?

deCODE Genetics has emerged from bankruptcy with a streamlined, diagnostics-oriented business model. In the near term, the privately held firm expects to offer its genomics discovery capabilities on a service basis, echoing the original genomics platform specialists of the late 1990s, including deCODE itself, which did largely unsuccessful technology deals focused on using genetic insight to generate therapies. The difference? It is now using genetic information to assess disease risk and better manage patient health, a strategy it thinks will succeed as the field of personalized medicine diagnostics continues to gain traction.

deCODE Re-Emerges: Can a Genomics Platform Model Work in Diagnostics?

deCODE Genetics has emerged from bankruptcy with a streamlined, diagnostics-oriented business model. In the near term, the privately held firm expects to offer its genomics discovery capabilities on a service basis, echoing the original genomics platform specialists of the late 1990s, including deCODE itself, which did largely unsuccessful technology deals focused on using genetic insight to generate therapies. The difference? It is now using genetic information to assess disease risk and better manage patient health, a strategy it thinks will succeed as the field of personalized medicine diagnostics continues to gain traction.

Start-Ups with Predictive ADME/Tox Technologies

Ask a head of R&D for a pharma or biotech to name the area where the need for new and better tools is greatest, and likely as not the answer will be predictive modeling of a drug's ADME/Tox profile. There's an abundance of sweet spots across the preclinical landscape for companies with better models and predictive tools.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel